Praxis Precision Medicines (PRAX) Cash & Equivalents (2019 - 2026)

Praxis Precision Medicines' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $536.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 223.94% year-over-year to $536.3 million in Q1 2026; TTM through Mar 2026 was $536.3 million, a 223.94% increase from a year earlier, with the FY2025 full-year figure at $357.3 million, up 65.91% from the prior year.
• Cash & Equivalents improved to $536.3 million in Q1 2026 per PRAX's latest filing, from $357.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $536.3 million in Q1 2026 and bottomed at $56.0 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $145.1 million (2024), against an average of $158.4 million.
• Across the five-year window, Cash & Equivalents plunged 68.14% in 2022 and jumped 223.94% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $61.6 million in 2022, then jumped by 31.95% to $81.3 million in 2023, then surged by 164.91% to $215.4 million in 2024, then soared by 65.91% to $357.3 million in 2025, then soared by 50.1% to $536.3 million in 2026.
• Per Business Quant, the three latest PRAX Cash & Equivalents figures stand at $536.3 million (Q1 2026), $357.3 million (Q4 2025), and $149.5 million (Q3 2025).